



THE LAW OFFICE OF
STEPHEN JOSEPH LASKERO
A California Law office
3451 Via Montebello, Suite 192-409
Carlsbad, CA 92009
stephenlaw7@ymail.com
760-452-6778

OTC Markets Group Inc.
300 Vesey Street, 12th Floor,
New York, NY 10282,
issuers@otcmarkets.com

June 24, 2022

Re: Attorney Letter for Lotus Bio-Technology Development Corp. Regarding Current Public Information

Dear Sir or Madam:

The purpose of this correspondence is to inform OTC Markets and the public of the availability of current public information for the “Issuer” Lotus Bio-Technology Development Corp. (LBTD), a Wyoming company. This law firm has been retained by the Issuer for the sole purpose of completing an opinion regarding the availability of current public information as that term is defined in Rule 144(c) (2) of the Securities Act of 1933 as amended. The OTC Markets Group is entitled to rely on this opinion and may publish this letter through the OTC Market Disclosure and News Service (otcmarkets.com) for the purpose of making this information available to the public.

The undersigned and sole author of this correspondence is licensed to practice law in the state of California, the United States District Court for the Southern District of California and is authorized to practice before the United States Securities and Exchange Commission (the “SEC”) and has not been disciplined or otherwise prohibited from that practice. The undersigned is not currently and never has been subject to an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission, the Financial Industry Regulatory Authority, or any other federal, state, or foreign entity. Moreover, the undersigned never has been and is not currently suspended or barred from practice in any foreign or domestic court of law or other tribunal or been charged in a civil or criminal case. Finally, the undersigned does not beneficially own any of the issuer’s stock and has not been promised any stock in the future for any reason whatsoever.

Limitations, Assumptions and Facts

In support of this opinion, the undersigned has reviewed applicable federal laws, rules and regulations including specifically the Securities Act of 1933 as amended and other relevant laws deemed necessary to render this opinion. The undersigned has also reviewed the corporate records determined to be appropriate, verified or assumed the legal capacity of all persons and entities, the genuineness of all signatures, the authenticity of all documents, and the veracity of all individuals who provided information regarding this matter.

In the portion of this letter that relies upon the information and documentation contained in the OTC disclosures of the issuer, the undersigned has not made, nor will he make any independent investigation regarding the representations contained therein. However, during my review of the documentation and conversations with the issuer's representatives, I did not reach the conclusion that any of the information I received was incorrect or disingenuous. Therefore, the information relied upon is believed to be true and reliable, and the documents genuine. This opinion is based solely on the facts, limitations and assumptions described in this letter and is not intended to be expanded to any other situation not discussed herein.

In the formation of the opinions contained in this letter, the undersigned has examined the following specific documents available by publication through the OTC Disclosure and News service as well as other available documents.:

PUBLISH DATE	TITLE	PERIOD END DATE
06/13/2022	ANNUAL REPORT-ANNUAL REPORT	03/31/2022
01/26/2022	QUARTERLY REPORT-AMENDEND QUARTERLY REPORT	12/31/2021
01/23/2022	QUARTERLY REPORT-DISCLOSURE STATEMENT Q3	12/31/2021
11/09/2021	QUARTERLY REPORT-DISCLOSURE STATEMENT	09/30/2021
09/20/2021	ATTORNEY LETTER WITH RESPECT TO CURRENT INFORMAITON- ATTORNEY OPINION REGARDING DISCLOSURE STATEMENTS	03/31/2021
09/09/2021	ANNUAL REPORT-ANNUAL REPORT AND DISCLOSURE STATEMENT	03/31/2019
09/01/2021	ANNUAL REPORT – AND DISCLOSURE STATEMENT	03/31/2021
09/01/2021	QUARTERLY REPORT-QUARTERLY REPORT	06/30/2021

The undersigned also reviewed the Pink Basic Disclosure Guidelines for the fiscal year ending December 31, 2019, December 31, 2020, and December 31, 2021.

The undersigned has met with Zoltan Nagy, the Chief Executive Officer, financial officer, and principal Director of Lotus Bio-Technology Development Corp., via telephone conference and email on several occasions. During these conversations, the information published by the issuer was discussed and confirmed to be accurate.

Prior to the Quarterly Report for the period ending September 30, 2021, the unaudited financial statements were prepared by Rachel Boulds, a Certified Public Accountant, who has identified herself as a service provider for the Company. Ms. Boulds is located at 6371 S. Glenoaks Street in Murray Utah. During our discussions, Ms. Boulds confirmed that she is a Certified Public Accountant, licensed in Utah with twenty years of public accounting experience.

The undersigned has also met via telephone conference with Rachel Boulds, the Certified Public Accountant responsible for the financial information contained in the above referenced OTC disclosures up to the quarterly report for period ending September 30, 2021. No discrepancies or disclaimers were reported regarding Ms. Boulds separation from the Company.

From that time forward, the reports were completed by Mr. Tam and Mr. Zoltan, the CEO of the company. I am informed and believe that Mr. Tam is a Chartered Professional Accountant with significant experience in preparing the financial reports necessary to complete the Annual and Quarterly reports for the Company. Mr Tam is located at 241 65th Ave E, Vancouver, BC V5X 2P3. It is also my understanding that Mr. Tam and Ms. Boulds have no other affiliation with the company.

The undersigned spoke to Mr. Tam by telephone who confirmed that he had knowledge of the reports and their contents. He also reported that the current reports were consistent with prior disclosures, and he found no irregularities in the Company's reporting. The disclosures including the Quarterly and Annual Reports since March 31, 2021, consist of primarily administrative and updated material information without significant changes. These reports were signed by Mr. Nagy, the CEO of the company who has adequate knowledge and understanding of the reporting process and the financial information in the reports. The company has been reporting consistently for the past 11 years. Since its inception in 2011, Mr. Nagy has taken an active role in the administration of the Company and the completion of the Annual, Quarterly and other reports filed on the OTC Disclosure and News Service. These reports contain adequate current public information regarding the Company.

The undersigned has received written confirmation that none of the individuals identified as owning 5% or more of the company's stock are currently under investigation by any federal or state agency for the violation of any securities laws, and never have been charged, indicted or been found guilty of any securities law violations including legal counsel. Consequently, to the best of my knowledge, after reasonable inquiry, the above referenced information can be relied upon by OTC Markets as being true and correct.

The undersigned confirmed the number of authorized and outstanding shares of the company by reviewing the information contained in the yearend financial statements, contacting the transfer agent, Colonial Stock Transfer Co. Inc., a licensed Securities Transfer Corp., and reviewing the company's "Security Details" available on the OTC Disclosure and News Service.

Non-Shell Status

According to the issuer's OTC disclosures it is not now and never has been a "shell company" as defined by Rule 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934. My factual inquiries support the conclusion that the company has been an ongoing concern since its inception and has more than nominal assets and operations as those terms are defined by the Securities Act. In its disclosures the Company has described itself as an ongoing concern attempting to reach its business goals. Moreover, on April 13, 2022, the company reported signing a Binding Letter of Intent to acquire up to 100% of the Little Jupiter Gold Project in Nevada, USA. A full explanation of the purpose of the proposed business venture and its forward-looking statements regarding the potential results are contained in the press release filed on the same date. Therefore, it appears that the company is not a "shell company" as that term is defined by the Act.

Legal Opinion

It is the undersigns opinion that the information provided by the issuer presents "adequate current public information" regarding the issuer and its securities that is available to the public as those terms are defined in Rule 144(c)(2) of the Securities Act of 1933. The available information all of the information a broker-dealer would need to publish a quote for the Securities under Rule 15c2-11 of the Securities Exchange Act of 1934, as amended. It also is consistent with OTC Markets Group's Pink Basic Disclosure Guidelines that have been published through the OTC Disclosure & News Service.

The opinions contained in this letter are limited to the laws of the United States, as well as the facts and circumstances described herein. Nothing in this correspondence should be construed as a guarantee or a definitive opinion of fact. All opinions assume that the presented documents and statements of management are true, and the facts delineated in the documents reviewed in support of this opinion are genuine.

The letter is being presented in accordance with the guidelines of the OTC Market Disclosure and New Service and OTC is hereby granted complete permission and rights to publish this letter. This correspondence applies only to law, facts and circumstances described herein and should not be relied upon by any other person or entity for any purpose. No other publication, use or reproduction of this correspondence is authorized without the specific written permission of the undersigned.

Regards,



Stephen Laskero
Attorney at Law